

# Robert Orenstein, Do

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/100591/publications.pdf>

Version: 2024-02-01

52  
papers

1,856  
citations

393982

19  
h-index

264894

42  
g-index

52  
all docs

52  
docs citations

52  
times ranked

2288  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Epidemiology of Community-Acquired Clostridium difficile Infection: A Population-Based Study. American Journal of Gastroenterology, 2012, 107, 89-95.	0.2	518
2	Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clinical Infectious Diseases, 2016, 62, 596-602.	2.9	140
3	Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660 Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2018, 67, 1198-1204.	2.9	96
4	Bacterial Complications of Strongyloidiasis: Streptococcus bovis Meningitis. Southern Medical Journal, 1999, 92, 728-731.	0.3	93
5	An outbreak of Mycobacterium chelonae infections in tattoos. Journal of the American Academy of Dermatology, 2010, 62, 501-506.	0.6	86
6	Asymptomatic Clostridium difficile colonization in a tertiary care hospital: Admission prevalence and risk factors. American Journal of Infection Control, 2013, 41, 390-393.	1.1	84
7	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. Mayo Clinic Proceedings, 2020, 95, 2382-2394.	1.4	77
8	A Targeted Strategy to Wipe Out Clostridium difficile. Infection Control and Hospital Epidemiology, 2011, 32, 1137-1139.	1.0	68
9	Successful Treatment of Disseminated Nonmeningeal Coccidioidomycosis with Voriconazole. Clinical Infectious Diseases, 2004, 39, e74-e77.	2.9	59
10	Characteristics of Patients with Mild to Moderate Primary Pulmonary Coccidioidomycosis. Emerging Infectious Diseases, 2014, 20, 983-90.	2.0	56
11	Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Mayo Clinic in Arizona Experience. Mayo Clinic Proceedings, 2013, 88, 799-805.	1.4	52
12	Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. Clinical Infectious Diseases, 2018, 66, 514-522.	2.9	51
13	An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurology, The, 2010, 9, 55-66.	4.9	48
14	Failure of Caspofungin to Treat Brain Abscesses Secondary to Candida albicans Prosthetic Valve Endocarditis. Clinical Infectious Diseases, 2004, 39, 1253-1254.	2.9	45
15	A Framework for Outpatient Infusion of Antispikes Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19. Mayo Clinic Proceedings, 2021, 96, 1250-1261.	1.4	45
16	Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1415-1420.	0.9	31
17	High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagnostic Microbiology and Infectious Disease, 2010, 66, 24-28.	0.8	30
18	A Randomized, Double Blind, Placebo-Controlled Trial of an Oral Synbiotic (AKSB) for Prevention of Travelers' Diarrhea. Journal of Travel Medicine, 2013, 20, 88-94.	1.4	28

#	ARTICLE	IF	CITATIONS
19	Fidaxomicin Failures in Recurrent Clostridium difficile Infection: A Problem of Timing. Clinical Infectious Diseases, 2012, 55, 613-614.	2.9	26
20	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. Mayo Clinic Proceedings, 2021, 96, 601-618.	1.4	20
21	Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection. Clinical Infectious Diseases, 2017, 65, 1214-1217.	2.9	20
22	Coccidioidal Tenosynovitis of the Hand and Wrist: Report of 9 Cases and Review of the Literature: Table 1.. Clinical Infectious Diseases, 2015, 61, 1514-1520.	2.9	15
23	Looking Beyond Highly Active Antiretroviral Therapy: Drug-Related Hepatotoxicity in Patients with Human Immunodeficiency Virus Infection. Pharmacotherapy, 2002, 22, 1468-1478.	1.2	14
24	The impact of early and brief corticosteroids on the clinical course of primary pulmonary coccidioidomycosis. Journal of Infection, 2013, 67, 148-155.	1.7	13
25	Moving Fecal Microbiota Transplantation Into the Mainstream. Nutrition in Clinical Practice, 2013, 28, 589-598.	1.1	13
26	Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482199404.	1.4	12
27	The risk of herpes zoster: another cost of anti-TNF therapy?. Nature Reviews Rheumatology, 2009, 5, 361-363.	3.5	11
28	S131 fCP101, an Investigational Orally Administered Microbiome Therapeutic, Increases Intestinal Microbiome Diversity and Prevents Recurrent C. difficile Infection: Results From a Randomized, Placebo-Controlled Trial. American Journal of Gastroenterology, 2021, 116, S57-S57.	0.2	11
29	Effect of Telephoned Notification of Positive Clostridium difficile Test Results on the Time to the Ordering of Antimicrobial Therapy. Infection Control and Hospital Epidemiology, 2008, 29, 658-660.	1.0	9
30	Preoperative risk prediction of surgical site infection requiring hospitalization or reoperation in patients undergoing vascular surgery. Journal of Vascular Surgery, 2016, 64, 177-184.	0.6	9
31	Research Response to SARS-CoV-2/COVID-19. Mayo Clinic Proceedings, 2020, 95, S52-S55.	1.4	8
32	Proteus mirabilis: A rare cause of infectious endocarditis. Scandinavian Journal of Infectious Diseases, 2007, 39, 373-375.	1.5	7
33	Travel in patients receiving TNF-alpha inhibitors. Travel Medicine and Infectious Disease, 2005, 3, 105-109.	1.5	6
34	A Woman with Fever and Rash after African Safari. Clinical Infectious Diseases, 2006, 43, 661-662.	2.9	6
35	Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature. Mycopathologia, 2016, 181, 787-798.	1.3	6
36	Clostridioides difficile therapeutics: guidelines and beyond. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611986854.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis. <i>Journal of NeuroVirology</i> , 2019, 25, 280-283.	1.0	6
38	Risk Factors for Urinary Lithotripsy-Associated Sepsis. <i>Infection Control and Hospital Epidemiology</i> , 1993, 14, 469-472.	1.0	5
39	Infections related to TNF- $\alpha$ inhibitors. <i>Expert Review of Dermatology</i> , 2006, 1, 737-749.	0.3	5
40	Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant <i>Staphylococcus aureus</i> . <i>Clinical Therapeutics</i> , 2007, 29, 381-383.	1.1	4
41	Mini-Fecal Microbiota Transplantation for Treatment of <i>Clostridium difficile</i> Proctitis Following Total Colectomy. <i>Clinical Infectious Diseases</i> , 2018, 66, 299-300.	2.9	3
42	A case of <i>Burkholderia pseudomallei</i> mycotic aneurysm linked to exposure in the Caribbean via whole genome sequencing. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac136.	0.4	3
43	Invasive <i>Haemophilus influenzae</i> . <i>Annals of Internal Medicine</i> , 1992, 117, 621.	2.0	2
44	Patient and Environmental Service Employee Satisfaction of Using Germicidal Bleach Wipes for Patient Room Cleaning. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2013, 35, 30-36.	0.3	2
45	Mo1952 “Efficacy of Oral Vancomycin Prophylaxis for Prevention of <i>Clostridioides Difficile</i> Infection: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2019, 156, S-897-S-898.	0.6	2
46	Polyneuritis cranialis after acute tularemia infection: A case study. <i>Muscle and Nerve</i> , 2020, 61, E1-E2.	1.0	2
47	Doxycycline for Switch Therapy in Community- Acquired Pneumonia. <i>Infectious Diseases in Clinical Practice</i> , 1999, 8, 465-466.	0.1	1
48	C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL. <i>Chest</i> , 2021, 160, A2522-A2524.	0.4	1
49	Metabolic and morphologic complications of HIV infection. <i>Journal Medical Libanais</i> , 2006, 54, 97-105.	0.0	1
50	HIV Infection in Primary Care. <i>Mayo Clinic Proceedings</i> , 2003, 78, 527.	1.4	0
51	Clinical Pearls in Infectious Diseases. <i>Mayo Clinic Proceedings</i> , 2010, 85, 172-175.	1.4	0
52	Zoster vaccine and biologic agents: time to question a paradigm?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 636-638.	3.5	0